AbCellera and Eli Lilly join hunt for coronavirus therapy

Canadian biotech AbCellera has joined forces with Eli Lilly to co-develop antibody products to prevent and treat COVID-19, the disease caused by the novel SARS-Cov-2 coronavirus.

Failed trial puts future of UCB’s epilepsy drug padsevonil i...

France’s MedDay says drug for MS falls at phase 3 hurdle

Sunak's first budget tackles pharma R&D as well as coronavir...

In his first budget as UK chancellor, Rishi Sunak’s main focus was to prepare the country for the impact of coronavirus – but there were other pharma-friendly measures in there too.

Takeda's Ninlaro falls short in first line multiple myeloma

Takeda’s Ninlaro (ixazomib) has fallen short in a late-stage study testing it in combination with Bristol-Myers Squibb/Celgene’s Revlimid and chemo in newly diagnosed multiple myeloma.

BMS backs record $600m European venture fund closed by LSP